Ticker >

Lupin share price

Lupin Ltd.

NSE: LUPIN BSE: 500257 SECTOR: Pharmaceuticals & Drugs  213k   778   125

1622.25
+17.65 (1.10%)
NSE: 12 Apr 04:05 PM

Price Summary

Today's High

₹ 1641.95

Today's Low

₹ 1597.9

52 Week High

₹ 1704.25

52 Week Low

₹ 655.4

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

73924.36 Cr.

Enterprise Value

74436.85 Cr.

No. of Shares

45.57 Cr.

P/E

35.87

P/B

3.66

Face Value

₹ 2

Div. Yield

0.25 %

Book Value (TTM)

₹  443.13

CASH

100.97 Cr.

DEBT

613.46 Cr.

Promoter Holding

47.01 %

EPS (TTM)

₹  45.23

Sales Growth

-4.36%

ROE

2.35 %

ROCE

3.3%

Profit Growth

325.34 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Lupin Ltd.

Molnulup Respira endeavour maxter pinnacle blue eyes femina midvision CVN

Index Presence

The company is present in 33 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-4.36%
3 Year0.7%
5 Year2.22%

Profit Growth

1 Year325.34%
3 Year-16.39%
5 Year-20.57%

ROE%

1 Year2.35%
3 Year2.79%
5 Year4.42%

ROCE %

1 Year3.3%
3 Year4.01%
5 Year6.57%

Debt/Equity

0.0336

Price to Cash Flow

41.21

Interest Cover Ratio

6.35493701747257

CFO/PAT (5 Yr. Avg.)

2.35153169870611

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 47.01 0
Dec 2023 47.04 0
Sep 2023 47.06 0
Jun 2023 47.07 0
Mar 2023 47.08 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company’s PEG ratio is 0.110332016873518.
  • The company has an efficient Cash Conversion Cycle of 65.8388069753683 days.
  • Company has a healthy liquidity position with current ratio of 2.08688892870433.
  • The company has a good cash flow management; CFO/PAT stands at 2.35153169870611.

 Limitations

  • The company has shown a poor profit growth of -16.3921847897256% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.700012611160772% for the Past 3 years.
  • Company has a poor ROE of 2.79069306074258% over the past 3 years.
  • Company has a poor ROCE of 4.00713860048793% over the past 3 years
  • The company is trading at a high PE of 35.87.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 2861.11 2836.27 3495.64 3659.23 4115.75
Total Expenditure 2651.09 2574.09 2790.62 2823.99 2898.41
Operating Profit 210.02 262.18 705.02 835.24 1217.34
Other Income 22.21 55.3 27.74 25.6 23.16
Interest 30.75 29.44 16.18 15.32 11.36
Depreciation 134.03 146.2 140.05 149.48 145.18
Exceptional Items 0 0 0 0 0
Profit Before Tax 67.45 141.84 576.53 696.04 1083.96
Tax 27.05 22.83 99.57 147.43 167.52
Profit After Tax 40.4 119.01 476.96 548.61 916.44
Adjusted EPS (Rs) 0.89 2.62 10.48 12.05 20.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 11356.32 11025.66 11055.93 11771.67 11258.83
Total Expenditure 8503.54 9118.05 9011.87 11566.69 10294.93
Operating Profit 2852.78 1907.61 2044.06 204.98 963.9
Other Income 291.34 475.19 129.09 221.15 210.02
Interest 35.47 52.59 40.62 73.47 98.44
Depreciation 426.3 518.75 502.83 514.19 548.34
Exceptional Items -339.98 -759.21 0 0 0
Profit Before Tax 2342.37 1052.25 1629.7 -161.53 527.14
Tax 803.54 324.7 371.08 27.17 101.93
Net Profit 1538.83 727.55 1258.62 -188.7 425.21
Adjusted EPS (Rs.) 34.01 16.06 27.74 -4.15 9.35

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 90.5 90.6 90.74 90.9 91
Total Reserves 17026.77 17382.6 18474.83 18059.29 18320.86
Borrowings 0.53 0.31 0.15 0 0
Other N/C liabilities 575.02 651.2 707.01 625.27 643.96
Current liabilities 1997.39 2555.79 2585.83 3537.91 3627.85
Total Liabilities 19690.21 20680.5 21858.56 22313.37 22683.67
Assets
Net Block 3372.95 3513.88 3638.83 3690.18 4021.93
Capital WIP 903.82 694.63 795.83 773.74 737.99
Intangible WIP 295.27 127.37 155.03 173.7 188.6
Investments 5281.09 5126.7 7241.59 8688.69 9534.56
Loans & Advances 348.68 376.38 399.62 537.04 603.86
Other N/C Assets 3.89 3.03 10.29 12.2 25.81
Current Assets 9484.51 10838.51 9617.37 8437.82 7570.92
Total Assets 19690.21 20680.5 21858.56 22313.37 22683.67
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 2342.37 1052.25 1629.7 -161.53 527.14
Adjustment 657.31 718.54 487.06 449.36 583.79
Changes in Assets & Liabilities 922.35 834.62 -118.04 -284.97 809.86
Tax Paid -811.31 -385.92 -428.64 148.17 -126.8
Operating Cash Flow 3110.72 2219.49 1570.08 151.03 1793.99
Investing Cash Flow -2865.07 -739.56 -2507.52 -371.79 -1269.17
Financing Cash Flow -295.38 -367.85 -53.17 102.45 -498.26
Net Cash Flow -49.73 1112.08 -990.61 -118.31 26.56

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 47.08 47.07 47.06 47.04 47.01
anuja gupta 0.16 0.16 0.16 0.16 0.16
desh bandhu gupta huf 0.14 0.14 0.14 0.14 0.14
kavita gupta 0.04 0.04 0.04 0.04 0.04
lupin investments pvt ltd... 45.54 45.53 45.52 45.50 45.47
manju d gupta 0.85 0.85 0.85 0.85 0.85
neel deshbandhu gupta 0.01 0.01 0.01 0.01 0.01
nilesh d gupta 0.20 0.20 0.20 0.20 0.20
richa gupta 0.05 0.05 0.05 0.05 0.05
veda nilesh gupta 0.02 0.02 0.02 0.02 0.02
vinita gupta 0.07 0.07 0.07 0.07 0.07
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 52.92 52.93 52.94 52.96 52.99
hdfc life insurance compa... 1.59 1.67 1.68 1.48 1.37
hdfc trustee company ltd-... 4.06 3.88 3.68 3.84 3.11
icici prudential value di... - - - - 4.31
investor education and pr... 0.16 - - 0.17 0.17
life insurance corporatio... 8.23 8.24 8.23 6.14 5.87
mirae asset large and mid... - - - 1.76 1.49
nippon life india trustee... 1.93 1.85 1.77 1.89 1.87
sbi long term equity fund... 1.12 - 1.09 1.23 1.14
government pension fund g... 1.57 1.57 1.38 1.12 -
icici prudential bluechip... 5.74 5.50 5.14 5.25 -
investor education and pr... - 0.16 0.17 - -
mirae asset emerging blue... - 1.28 1.68 - -
nps trust - a/c hdfc pens... - - 1.02 - -
nps trust - a/c lic pensi... - 1.23 - - -
dsp tax saver fund 1.02 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Lupin informs about press release12 Apr 2024, 5:27PM USFDA completes GMP inspection at Lupin’s API manufacturing facility at Dabhasa12 Apr 2024, 4:00PM Lupin recalls 26,352 bottles of Rifampin Capsules in US market10 Apr 2024, 4:38PM Lupin launches first generic version of Oracea in United States10 Apr 2024, 9:17AM Lupin receives USFDA’s approval for Valbenazine Capsules9 Apr 2024, 12:45PM Lupin informs about compliances-certificate 5 Apr 2024, 5:02PM Lupin informs about updates2 Apr 2024, 3:33PM Lupin gets nod to transfer trade generics business in India to Lupin Life Sciences 23 Mar 2024, 11:15AM Lupin informs about closure of trading window22 Mar 2024, 2:51PM Lupin informs about stop transfer19 Mar 2024, 12:47PM Lupin informs about change in management 18 Mar 2024, 4:32PM Lupin receives USFDA’s approval for Minzoya tablets16 Feb 2024, 2:41PM Lupin launches Ganirelix Acetate Injection15 Feb 2024, 2:05PM Lupin informs about press release 15 Feb 2024, 1:16PM Lupin launches Bromfenac Ophthalmic Solution13 Feb 2024, 4:30PM Lupin reports around 4-fold jump in Q3 consolidated net profit8 Feb 2024, 11:20AM Lupin - Quaterly Results7 Feb 2024, 7:39PM Lupin - Quaterly Results7 Feb 2024, 7:39PM Lupin receives USFDA’s approval for Bromfenac Ophthalmic Solution7 Feb 2024, 11:19AM Lupin receives USFDA’s approval for Dronedarone Tablets1 Feb 2024, 3:40PM Lupin submits board meeting intimation24 Jan 2024, 4:33PM Lupin gets tentative nod for Rivaroxaban Tablets24 Jan 2024, 10:08AM Lupin informs about details of loss of certificate19 Jan 2024, 6:02PM Lupin gets USFDA’s nod for Febuxostat Tablets 18 Jan 2024, 5:34PM Lupin gets nod for Propranolol Hydrochloride Extended-Release Capsules 15 Jan 2024, 9:30AM Lupin informs about loss of share certificate11 Jan 2024, 3:57PM Lupin informs about press release10 Jan 2024, 2:28PM Lupin launches Varenicline Tablets10 Jan 2024, 12:59PM Lupin launches Bromfenac Ophthalmic Solution9 Jan 2024, 6:14PM Lupin gets USFDA’s tentative approval for Dapagliflozin and Saxagliptin Tablets5 Jan 2024, 9:29AM Lupin receives USFDA’s approval for Loteprednol Etabonate Ophthalmic Suspension27 Dec 2023, 5:12PM Lupin's arm signs agreement with Sanofi to acquire established pharmaceutical products in Europe, Canada22 Dec 2023, 2:10PM Lupin launches Softovac Liquifibre21 Dec 2023, 5:27PM Lupin informs about stop transfer request 21 Dec 2023, 2:12PM Lupin’s arm recalls penicillamine tablets in US18 Dec 2023, 2:30PM Lupin gets approval from USFDA for Allopurinol Tablets15 Dec 2023, 6:00PM Lupin gets USFDA’s tentative nod for Sitagliptin Tablets15 Dec 2023, 5:06PM Lupin informs about press release 14 Dec 2023, 5:29PM Lupin informs about granted stock options14 Dec 2023, 5:09PM Lupin’ arm launches new regional reference laboratory in Chennai14 Dec 2023, 2:27PM Lupin informs about loss of share certificates7 Dec 2023, 3:01PM Lupin informs about press release6 Dec 2023, 10:16AM Lupin receives approval from USFDA for Varenicline Tablets6 Dec 2023, 9:58AM Lupin launches Turqoz tablets in United States1 Dec 2023, 5:11PM Lupin informs about details of loss of certificate 24 Nov 2023, 5:01PM Lupin informs about allotment of ESOP 24 Nov 2023, 2:58PM Lupin gets USFDA’s tentative nod for Canagliflozin Tablets23 Nov 2023, 4:22PM Lupin gets USFDA’s approval for Bromfenac Ophthalmic Solution23 Nov 2023, 4:08PM Lupin informs about press release 23 Nov 2023, 12:52PM Lupin launches world’s first fixed-dose triple combination drug ‘Vilfuro-G’23 Nov 2023, 11:42AM

Lupin Stock Price Analysis and Quick Research Report. Is Lupin an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lupin and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Lupin cash from the operating activity was Rs 1793.99 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lupin has a Debt to Equity ratio of 0.0336 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lupin , the EPS growth was 325.090322269859 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lupin has OPM of 8.56128034618162 % which is a bad sign for profitability.
     
  • ROE: Lupin have a poor ROE of 2.34585936870724 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Lupin is Rs 1622.25. One can use valuation calculators of ticker to know if Lupin share price is undervalued or overvalued.
Last Updated on:
Brief about Lupin

Lupin Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Welcome to our Lupin Ltd. stock analysis page, where long-term investors can find a wealth of information and resources to make informed decisions about their investment positions. We provide a comprehensive analysis of various aspects of Lupin Ltd.'s stock performance, allowing investors to gain valuable insights into the company's financial stability, growth prospects, and long-term viability. Let us delve into each topic in detail.

Lupin Ltd. Share Price Analysis

Analyzing the share price of Lupin Ltd. is crucial for long-term investors to understand the company's growth potential and market sentiment. Our pre-built screening tools enable investors to track the historical share price of Lupin Ltd. over different timeframes. By studying price trends, trading volumes, trading range, and the stock's relative performance compared to market indices, investors gain insights into Lupin Ltd.'s financial stability, growth prospects, and investment viability. In addition to these screening tools, our platform provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which offer a more comprehensive analysis of Lupin Ltd.'s intrinsic value and growth potential.

Lupin Ltd. Balance Sheet Evaluation

Evaluating Lupin Ltd.'s balance sheet is a critical step for long-term investors to understand the company's financial position and growth potential. Our pre-built screening tools enable investors to determine Lupin Ltd.'s balance sheet ratios and metrics. By examining key financial indicators such as current assets, current liabilities, and long-term debt, investors gain insights into Lupin Ltd.'s financial stability, liquidity, and potential for growth. Additionally, our platform provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which provide a more comprehensive analysis of Lupin Ltd.'s balance sheet, helping investors assess its long-term investment potential.

Lupin Ltd. Annual Report Insights

Lupin Ltd.'s annual reports offer a wealth of information about the company's performance, strategies, and plans. On our platform, you can access downloadable PDF versions of Lupin Ltd.'s annual reports, along with expert reviews and analysis. These annual reports provide insights into Lupin Ltd.'s business model, competitive landscape, and macroeconomic factors that may impact its operations. Coupled with our premium features tools, investors can conduct a thorough analysis and make well-informed decisions based on Lupin Ltd.'s annual reports.

Lupin Ltd. Dividend Payments

Analysing Lupin Ltd.'s dividend payments is crucial for long-term investors seeking stable returns. Our stock analysis page provides comprehensive data on the company's dividend payment history. By analysing Lupin Ltd.'s profitability, dividend policy, and metrics such as the dividend yield and payout ratio, investors can make well-informed decisions about their long-term investment positions. Alongside our dividend payment information, our platform offers premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which allow investors to evaluate the impact of dividends on Lupin Ltd.'s stock value and overall investment strategy.

Lupin Ltd. Quarterly Results Analysis

Analyzing Lupin Ltd.'s quarterly results helps investors evaluate its short-term performance and gauge its future growth potential. On our platform, you can find downloadable PDF files of Lupin Ltd.'s quarterly results, enabling investors to assess the company's recent performance and key financial metrics such as revenue growth, earnings per share, and margins. By leveraging our premium features tools and conducting a thorough analysis, long-term investors can make well-informed decisions regarding their investment positions in Lupin Ltd.

Lupin Ltd. Stock Price Trends

Analyzing Lupin Ltd.'s stock price trends is essential for understanding its growth potential and market sentiment. Our pre-built screening tools enable investors to track Lupin Ltd.'s stock price trends over different timeframes. This allows the identification of short-term and long-term patterns and pricing volatility. By utilizing our premium features tools, investors gain additional insights into factors affecting Lupin Ltd.'s stock performance, aiding them in making well-informed decisions.

Lupin Ltd. Price Charts

Technical analysis through price chart analysis provides additional insights into Lupin Ltd.'s stock performance. On our website, you can access dynamic price charts that display historical price movements, technical indicators, and patterns. These charts assist investors in identifying potential entry and exit points, support and resistance levels, and trend reversals. By incorporating these insights into our premium features tools, investors can conduct a comprehensive analysis and make informed decisions about Lupin Ltd. as a long-term investment.

Lupin Ltd. News Updates

Keeping up with the latest news and developments concerning Lupin Ltd. is fundamental for long-term investors. Our website provides comprehensive and timely information sourced from reliable news channels. Through articles and news updates, investors gain insights into Lupin Ltd.'s industry trends, market position, and future outlook. This information empowers investors to make well-informed decisions and stay ahead of market dynamics affecting their long-term investment positions.

Lupin Ltd. Conference Calls

Lupin Ltd.'s conference calls offer crucial insights into the company's operations, financial performance, and growth strategies. On our platform, you can find a searchable collection of Lupin Ltd.'s conference calls, including downloadable recordings. By listening to these calls, investors gain a deep understanding of Lupin Ltd.'s management team, growth plans, and economic factors impacting the company's performance. Leveraging our premium features tools, investors can carry out comprehensive analyses and make well-informed decisions regarding their long-term investment positions in Lupin Ltd.

Lupin Ltd. Transcripts

Transcripts of Lupin Ltd.'s conference calls capture important discussions and insights. Our platform provides downloadable transcripts that include in-depth analyses of the company's financial performance, future plans, and market trends. Reviewing these transcripts offers valuable insights into Lupin Ltd.'s strategies, growth potential, and adaptability to market dynamics. By leveraging our premium features tools and conducting a comprehensive analysis, investors can make well-informed decisions about Lupin Ltd. as a long-term investment.

Lupin Ltd. Investor Presentations

Lupin Ltd.'s investor presentations offer detailed information about the company's financials, strategic initiatives, and future plans. On our platform, you can easily access these investor presentations in downloadable PDF format. These presentations provide insights beyond the numbers, delving deep into Lupin Ltd.'s growth strategy, market expansion plans, and competitive advantages. By leveraging our premium features tools and conducting thorough analyses, investors can make sound investment decisions based on Lupin Ltd.'s investor presentations.

Lupin Ltd. Promoters and Shareholders

Understanding the ownership structure of Lupin Ltd. is crucial for long-term investors evaluating the company's growth potential and stability. Our pre-built screening tools enable investors to assess promoter holdings and analyze the company's shareholder base. By understanding the distribution of ownership and the alignment of interests, investors can make well-informed decisions about their long-term investment positions in Lupin Ltd.

Lupin Ltd. ROCE

Return on Capital Employed (ROCE) is a key financial metric that indicates the efficiency and profitability of a company's capital investments. It is a crucial factor in evaluating Lupin Ltd.'s financial performance. You can conveniently access ROCE data for Lupin Ltd. in the financials table or ratio section on this page.

Lupin Ltd. EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) provides insight into Lupin Ltd.'s operating profitability. This metric is essential for assessing the company's financial health. Detailed EBITDA data for Lupin Ltd. can be found in the financials table or ratio section located on this page.

Lupin Ltd. DPS

Dividends Per Share (DPS) is a vital indicator for investors seeking information about the dividend distribution of Lupin Ltd. This page offers access to DPS data as it pertains to the company, which aids in evaluating its dividend policy and performance.

Lupin Ltd. EPS

Earnings Per Share (EPS) is a fundamental metric for analyzing Lupin Ltd.'s profitability and investment potential. This information is readily available on this page in the financials table or ratio section. EPS data allows for a comprehensive assessment of the company’s earnings and financial outlook.

Read More
X